A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue

Laboratory Investigation

Volumn 87, Issue 4, 2007, Pages 392-397

  Cankovic, Milena ^a   Mikkelsen, Tom ^a   Rosenblum, Mark L ^a   Zarbo, Richard J ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Formalin fixed tissue; Glioblastoma multiforme; Methylation specific PCR; MGMT; Promoter hypermethylation; Temozolomide

Indexed keywords

BISULFITE; FORMALDEHYDE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PARAFFIN;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENE AMPLIFICATION; GENE SILENCING; GENETIC ANALYSIS; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METHYLATION; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RELIABILITY; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASTROCYTOMA; BRAIN NEOPLASMS; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; FIXATIVES; FORMALDEHYDE; GENE SILENCING; GLIOBLASTOMA; HUMANS; MALE; METHYLATION; MIDDLE AGED; OLIGODENDROGLIOMA; PARAFFIN EMBEDDING; PROMOTER REGIONS (GENETICS); REPRODUCIBILITY OF RESULTS; TUMOR SUPPRESSOR PROTEINS;

EID: 33947536116     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700520     Document Type: Article

References (27)

1. Hulleman E, Helin K. Molecular mechanisms in gliomagenesis. Adv Cancer Res 2005;94:1-21.
2. Andesson U, Malmer B, Bergenheim AT, et al. Heterogeneity in the expression markers of drug resistance in brain tumors. Clin Neuropathol 2004;23:21-27.
3. Nieder C, Adam M, Grosu AL. Combined modality treatment of glioblastoma multiforme: the role of Temozolomide. Rev Recent Clin Trials 2006;1:43-51.
4. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from Temozolomide in glioblastomas. N Engl J Med 2005;352:997-1003.
5. Stupp R, Dietrich P-Y, Kraljevic SO. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus Temozolomide followed by adjuvant Temozolomide. J Clin Oncol 2002;20:1375-1382.
6. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000;6:2585-2597.
7. Kaina B, Christmann M. DNA repair in resistance to alkylating anticancer drugs. Int J Clin Pharmacol Ther 2002;40:354-367.
8. Gerson SL. MGMT: its role in cancer etiology and cancer therapeutics. Nat Rev Cancer 2004;4:296-307.
9. 6-methylguanine DNA methyltransferase in human cancer. Oncogene 2004;23:1-8.
10. 6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bischloroethylnitrosourea: a Southwest Oncology Group Study. J Clin Oncol 1998;16:3310-3315.
11. Hegi ME, Diserens A-C, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10:1871-1874.
12. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-1354.
13. 6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Cin Cancer Res 2005;11:5167-5174.
14. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-2054.
15. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-167.
16. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000;16:168-174.
17. Costello JE, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has nonrandom and tumour-type-specific patterns. Nat Genet 2000;24:132-138.
18. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-692.
19. INK4B. Cancer Res 1996;56:722-727.
20. Esteller M, Hamilton SR, Burger PC, et al. Inactivation of the DNA repair gene O-6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-797.
21. Rein T, DePamphilis ML, Zorbas H. Identifying 5-methylcytosine and related modifications in DNA genomes. Nucleic Acids Res 1998;26:2255-2264.
22. Gonzalez-Gomez P, Bello MJ, Arjona D, et al. Promoter hypermethylation of multiple genes in astrocytic gliomas. Int J Oncol 2003;22:601-608.
23. Zochbauer-Muller S, Fong KM, Virmani AK, et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001;61:249-255.
24. 6methylguanine-DNA methyltransferase gene expression in gliomas by means of real-time quantitative RT-PCR and clinical response to nitrosoureas. Int J Cancer 2003;103:67-72.
25. 6methylguanine-DNA methyltransferase gene (MGMT) expression in human glioblastomas in relation to patient characteristics and p53 accumulation. Int J Cancer 1999;416:416-420.
26. Möllemann M, Wolter M, Felsberg J, et al. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2005;113:379-385.
27. Ogino S, Kawasaki T, Brahmandam M, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (Mehtyl Light) for quantitative DNA methylation analysis. J Mol Diagnostics 2006;8:209-217.